Prescription drug · NDA
Kyxata (carboplatin) NDC 83831-142
Carboplatin 500 mg/50mL · Injection · Intravenous · Avyxa Pharma, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 83831-142-50 | 83831014250 | 1 VIAL, MULTI-DOSE in 1 CARTON (83831-142-50) / 50 mL in 1 VIAL, MULTI-DOSEMarketed from Sep 10, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Kyxata
- Generic name (nonproprietary)
- carboplatin
- Active ingredients
- Carboplatin — 500 mg/50mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- Avyxa Pharma, LLC
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 219921
- Marketing start
- Listing expires
- Other FDA classes
- Platinum-containing Compounds (EXT)
- Identifiers
- Product ID 83831-142_5c711945-70be-42f4-b153-e1459dd9929cSPL ID 5c711945-70be-42f4-b153-e1459dd9929cSPL set ID f91c48da-68d1-4aa7-89b8-d84a3e8b629bRxCUI 597195, 2721602UNII BG3F62OND5UPC 0383831142508, 0383831141082
- Pharmacologic class
- Platinum-based Drug
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N483831014250followed by a unit qualifier and the quantityPackage 83831-0142-50. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
KYXATA is a platinum-based drug indicated in adults: As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. ( 1.1 ) As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy. ( 1.2 ) 1.1 Initial Treatment of Advanced Ovarian Carcinoma KYXATA, as part of a combination regimen, is indicated for the initial treatment of adults with advanced ovarian carcinoma. 1.2 Recurrent Advanced Ovarian Carcinoma KYXATA is indicated for treatment of adults with ovarian carcinoma recurrent after prior chemotherapy.
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 219921
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Kyxatacarboplatin | Carboplatin 80 mg/8mL | InjectionIntravenous | Avyxa Pharma, LLC | 83831-141 |